

Attorney's Docket No. 33339/176332



7/17/653  
Harry  
Jan. 13, 02  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
JAN 04 2002  
TECH CENTER 1600/2900

In re:	Guy Serre, et al.	Confirmation No.:	
Appl No.:	09/254,032	Group Art Unit:	1653
Filed:	April 26, 1999	Examiner:	H. Robinson
For:	ANTIGENS DERIVED FROM FILAGGRIN AND THEIR USE FOR DIAGNOSING RHEUMATOID POLYARTHRITIS"		

October 29, 2001

Commissioner for Patents  
Washington, DC 20231

**ELECTION WITH TRAVERSE**

In response to the requirement for restriction mailed October 2, 2001, applicant provisionally elects the claims of Group I, namely Claims 1-6 drawn to an artificial antigen and an in vitro diagnosis process.

Applicant respectfully traverses the requirement for restriction, and requests reconsideration by the Examiner. The present application is the U.S. National Stage of a PCT Application. It appears that the Examiner has applied the United States standards, rather than the PCT Unity of Invention Standards. The common technical feature which is shared by all of the claims is the artificial antigen of Claims 1-4. This same technical feature is present in Claims 7-10. Thus, it clearly appears that the claims of Group I and Group II form a single general inventive concept and that the requirement of Unity of Invention, as defined in PCT Rule 13.1 is fulfilled.

Accordingly, reconsideration by the Examiner, withdrawal of the requirement for restriction, and an action on the merits of the claims as presented are earnestly solicited.


Respectfully submitted,



Raymond O. Linker, Jr.  
Registration No. 26,419

CUSTOMER NO. 00826  
ALSTON & BIRD LLP  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111

I hereby certify that this correspondence is being:

MAILING	FACSIMILE
<p><input checked="" type="checkbox"/> deposited with the United States Postal service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on October 29, 2001.</p> <p> Lorna Morehead</p>	<p><input type="checkbox"/> facsimile transmitted to the Patent and Trademark Office at _____, on October 29, 2001.</p> <p>_____ Signature</p>